 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
19 News |  |
- lacosamide / Generic mfg.
Neither Food nor the Use of Sprinkle Delivery Impacts the Oral Bioavailability of a Novel Extended-release Formulation of Lacosamide (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_1269;
Coadministration of lacosamide XR with a high-fat meal or the use of a sprinkle administration do not affect the overall exposure of lacosamide. Lacosamide XR capsules can be taken with or without meals and can be used as a sprinkle.
- || lacosamide extended release (ADS-4101) / Supernus Pharma
PK/PD data, Journal: Lacosamide extended-release capsules are bioequivalent to lacosamide immediate-release tablets: Pharmacokinetic observations and simulations. (Pubmed Central) - May 1, 2024
Pharmacokinetic simulations indicated lacosamide XR and IR formulations were similarly affected by partial adherence, though once-daily dosing with lacosamide XR may offer clinical advantages, and formulations can be easily switched. These results support the use of lacosamide XR capsules as a once-daily alternative to lacosamide IR tablets.
- || lacosamide / Generic mfg.
Clinical, Retrospective data, Journal, Monotherapy: Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: Post hoc analysis of a randomized, double-blind trial. (Pubmed Central) - Nov 13, 2023
P3
These results support the use of lacosamide XR capsules as a once-daily alternative to lacosamide IR tablets. Lacosamide was efficacious and generally well tolerated as monotherapy in patients with TLE with efficacy outcomes comparable with CBZ-CR, and fewer patients on LCM reported any TEAEs, drug-related TEAEs, or discontinued due to TEAEs.
- || lacosamide extended release (ADS-4101) / Supernus Pharma
New P1 trial: An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Two-way Crossover, Oralcomparative Pharmacokinetic?PK?Study of Lacosamide Extended-Release Tablets , Adult, Human Subjects Under Fasting Conditions. (clinicaltrials.gov) - Mar 28, 2023
P1, N=16, Not yet recruiting, Sponsor: Overseas Pharmaceuticals, Ltd.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Retrospective data, Journal, Monotherapy: Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial. (Pubmed Central) - Jul 2, 2021
P3
This exploratory post hoc analysis indicated that lacosamide monotherapy was efficacious and generally well tolerated in patients with newly diagnosed epilepsy and concomitant psychiatric conditions. In this subpopulation, lacosamide showed similar efficacy and numerically better effectiveness than carbamazepine-CR.
- || Vimpat (lacosamide) / UCB, carbamazepine / Generic mfg.
Clinical, Journal, Monotherapy: Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. (Pubmed Central) - Apr 16, 2020
P3
Long-term (median ~2 years) lacosamide monotherapy was efficacious and generally well tolerated in adults with newly diagnosed epilepsy. Seizure freedom rates were similar with lacosamide and carbamazepine-CR.